Cannabinoid Therapy for Pediatric Epilepsy

Summary

This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome. This is an open label intervention. Study duration is 20 weeks to primary analysis with continued follow-up until 64 weeks completed.

Timeline

Start

2017-02-02

Primary completion

2018-08-24

Completion

2021-07-20

Drugs

Indications